Klefström lab / Klefström lab

Klefström lab

Oncogenic signaling pathways as therapeutic targets in breast cancer

Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.

Learn more

Pharmacological intervention of SARS-CoV-2 entry mechanisms by blockade of TMPRSS activity

The Klefström laboratory has been identifying and developing chemical and pharmacological inhibitors against hepsin/TMPRSS family members for a long time with the goal of preventing cancer invasion. Some of our drugs or drug-like molecules could be repurposed to prevent SARS-CoV-2 entry to cells, potentially offering a fast-track treatment option for the COVID-19 disease.

Read more

Public Outreach – Follow our team!

Klefström lab on facebook

Great news! CancerIO is launching in Finland. 🥳

"The coming age of IO will have a transformative impact on fundamental and clinical cancer research, healthcare systems, business and, most importantly, on the lives of cancer patients."

Check out the whole article:

... See MoreSee Less

View on Facebook

Klefalabmeeting in the era of coronavirus ... See MoreSee Less

View on Facebook

3 months ago

Klefström Research Group

Congratulations to all the finalists of the CancerChallenge.eu who pitched their ideas about how to improve cancer prevention, research, treatment and life with cancer.

One of our own, Shishir, gave a strong pitch as one of the top six (out of 119 great ideas). The winners will be announced on Wednesday. Good luck!

#syöpähaaste #eucancerchallenge
... See MoreSee Less

View on Facebook

We need new ways to translate scientific discoveries to early phase clinical testing Jeroen Pouwels ... See MoreSee Less

View on Facebook

Research Programs Unit/Translational Cancer Biology
& Medicum, Biomedicum Helsinki 1,
Medical Faculty, University of Helsinki

Haartmaninkatu 8
00290 Helsinki

University of Helsinki internal mailing address
P.O. Box 63
FI-00014 University of Helsinki

Tel. Lab +358 2 941 25494 (room B509)
Office +358 2 941 25493 (room B507b)
Junior office (room B503)
Fax +358 2 941 25610